| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Fernando De Andrés | Q56868336 |
| Andrea Negro | Q57014919 | ||
| Giovanna Gentile | Q57019868 | ||
| Martina Curto | Q59134368 | ||
| P2093 | author name string | Paolo Martelletti | |
| Luana Lionetto | |||
| Matilde Capi | |||
| P2860 | cites work | A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine | Q26823673 |
| Migraine and triggers: post hoc ergo propter hoc? | Q27026183 | ||
| Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison | Q28201298 | ||
| Patient satisfaction with eletriptan in the acute treatment of migraine in primary care | Q28221721 | ||
| The International Classification of Headache Disorders, 3rd edition (beta version) | Q29392338 | ||
| Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. | Q33889433 | ||
| Mechanisms of action of the 5-HT1B/1D receptor agonists | Q33960161 | ||
| Treatment of acute migraine headache. | Q34163270 | ||
| Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan | Q34205990 | ||
| Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review | Q34235325 | ||
| Eletriptan for acute migraine headaches in adults | Q34250923 | ||
| Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels | Q34388131 | ||
| Acute Migraine Treatment in Adults | Q34471863 | ||
| Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery | Q34548443 | ||
| The stress and migraine interaction. | Q34610075 | ||
| Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials | Q34647375 | ||
| In vitro and in vivo drug interactions involving human CYP3A. | Q34663451 | ||
| Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development | Q34985984 | ||
| Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans | Q35091964 | ||
| Tolerability and Safety of Eletriptan in the Treatment of Migraine: A Comprehensive Review | Q35544340 | ||
| Migraine: multiple processes, complex pathophysiology | Q35547845 | ||
| Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis | Q35692944 | ||
| Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms | Q35779019 | ||
| Safety and efficacy of eletriptan in the treatment of acute migraine | Q36408742 | ||
| Eletriptan: a review of its use in the acute treatment of migraine | Q36514170 | ||
| Triptans in pregnancy | Q36817033 | ||
| Frovatriptan review | Q37000753 | ||
| Individual triptan selection in migraine attack therapy | Q37370700 | ||
| Migraine in the triptan era: progresses achieved, lessons learned and future developments | Q37558323 | ||
| Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy | Q37818258 | ||
| Pharmacokinetic evaluation of frovatriptan | Q37935031 | ||
| The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies | Q38087404 | ||
| Migraine attack treatment : a tailor-made suit, not one size fits all. | Q38194179 | ||
| The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies | Q38323922 | ||
| Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations | Q38734042 | ||
| Headache and migraine: a leading cause of absenteeism | Q38943237 | ||
| Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States | Q39397606 | ||
| Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study | Q39401888 | ||
| Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks | Q39407492 | ||
| Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences | Q42280369 | ||
| Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study | Q43173466 | ||
| Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain | Q43713478 | ||
| Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers | Q43836982 | ||
| Outcome for headache and pain-free nonresponders to treatment of the first attack: a pooled post-hoc analysis of four randomized trials of eletriptan 40 mg. | Q43918311 | ||
| The pharmacokinetics and safety of single escalating oral doses of eletriptan | Q43997710 | ||
| Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration | Q43997713 | ||
| Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. | Q44326428 | ||
| Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein | Q44483226 | ||
| Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system | Q44511927 | ||
| Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients | Q44514106 | ||
| Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study | Q44601043 | ||
| Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine | Q44655384 | ||
| Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine | Q44776561 | ||
| Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis | Q45848154 | ||
| Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing | Q46657525 | ||
| Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. | Q53339904 | ||
| Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist | Q61650976 | ||
| Pharmacology and efficacy of eletriptan for the treatment of migraine attacks | Q73547436 | ||
| Efficacy of eletriptan in triptan-naïve patients: results of a combined analysis | Q79774216 | ||
| Myocardial infarction after taking eletriptan | Q87654285 | ||
| Eletriptan | Q94946247 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | migraine | Q133823 |
| eletriptan | Q415032 | ||
| P304 | page(s) | 414-423 | |
| P577 | publication date | 2016-09-01 | |
| P1433 | published in | Therapeutic advances in neurological disorders | Q26842039 |
| P1476 | title | Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response | |
| P478 | volume | 9 |
| Q48131347 | Acute treatment of migraine: quo vadis? |
| Q30831647 | Network meta-analysis of migraine disorder treatment by NSAIDs and triptans |
| Q47309054 | Side effects associated with current and prospective antimigraine pharmacotherapies. |
| Q91783277 | Synthesis of non-racemic 4-nitro-2-sulfonylbutan-1-ones via Ni(II)-catalyzed asymmetric Michael reaction of β-ketosulfones |
Search more.